Brind.

Major pharmaceutical companies, including BioNTech, DUALITY, Roche, and AstraZeneca, are competing in the Antibody-Drug Conjugate (ADC) market for breast cancer treatments.

Steady: 2 developments in the last 24 hours, 2 in the last 7 days Updated yesterday

The latest in this situation

  1. ADC Therapeutics also began using LinkedIn and received conditional approval from the EC.
  2. ADC Therapeutics secured conditional approval for its drug from the European Commission.

How it started

3 reports, 2 independent, last reported Sep 14. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Major pharmaceutical companies, including BioNTech, DUALITY, Roche, and AstraZeneca, are competing in the Antibody-Drug Conjugate (ADC) market for breast cancer treatments.

Who's involved

What this event is mainly about
Hoffmann-La RocheBioNTechDUALITYAstraZeneca

How it developed

Newest first. Tap a step to see who reported it.
  1. Astex Pharmaceuticals and Newcastle University formed a strategic alliance with Hoffmann-La Roche to license breast cancer compounds.Sub-event
  2. Pfizer and Genmab are collaborating on TIVDAK, which combines Genmab's antibody with Pfizer's ADC technology.Sub-event
  3. ADC Therapeutics received accelerated approval for its drug from the FDA.Sub-event
  4. Adagene Inc. presented data regarding its ADG126 therapy at a CSCO meeting, with mentions of locations including Jinan and Suzhou.Sub-event
  5. Hutchison MediPharma and AstraZeneca are jointly developing savolitinib TKI, with clinical data presentations scheduled for WCLC 2025 and CSCO Annual Meeting 2025.Sub-event
  6. Rivals are competing in the ADC market, with co-developers of trastuzumab pamirtecan highlighted.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • proactiveinvestors.com
  • Clinical Trials ArenaBioNTech and Duality’s ADC trumps Kadcyla, but analysts unimpressed BioNTech and DualityBio are seeking the Chinese approval of trastuzumab pamirtecan after it outperformed Roche’s Kadcyla (trastuzum
1 more outlet ran the same wire story